Strain Data Sheet


Strain Information

BRC No.RBRC02285
TypeTargeted Mutation and TransgeneCartagena
SpeciesMus musculus
Strain nameC57BL/6-St3gal4<tm1.1Bsi>
Former Common nameST34(#9 CAGCre)C57BL/6J:913 line, 913, C57BL/6-St3gal4<tm1.1Bsi> Tg(CAG-cre)913Bsi
H-2 Haplotype
ES Cell lineMS12 [C57BL/6]
Background strainC57BL/6JJcl
Appearanceblack [a/a B/B C/C]
Strain developmentDeveloped by Dr. Yoshio Hirabayashi, RIKEN BSI in 2004. St3gal4 null allele (St3gal4<tm1.1Bsi>) was generated by transient cre expression MS12 ES cells from St3gal4<tm1Bsi> that having a loxP flanked site in this allele.
Strain descriptionSt3gal4 (ST3GAL IV) knockout mouse. St3gal4 is one of alpha 2,3-sialyltransferases that is abundantly expressed in adult placenta, ovary, and testis.
Colony maintenanceBackcross to C57BL/6 (Heterozygote x C57BL/6JJcl))

Health Report

Examination Date / Room / Rack


Gene info
Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter
St3gal4ST3 beta-galactoside alpha-2,3-sialyltransferase 49St3gal4<tm1.1Bsi>targeted mutation 1.1, RIKEN BSISiat4c, ST3Gal IV

Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter
loxPphage P1 loxP9loxP

Ordering Information

Donor DNAmouse ST3Gal IV genomic DNA, phage P1 loxP, CAG promoter (CMV-IE enhancer, chicken beta-actin promoter, rabbit beta-globin genomic DNA)
Research applicationMetabolism Research
Mouse Models for Human Disease
Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. 1. The RECIPIENT agrees to use BIOLOGICAL RESOURCE only for academic research which is expected to be publicized in scientific papers.
2. The RECIPIENT will obtain a prior written consent on the use of BIOLOGICAL RESOURCE from the DEPOSIOR/DEVELOPER. At the same time, the RECIPENT will give the DEPOSITOR/DEVELOPER the details of the research project using BIOLOGICAL RESOURCE for the DEPOSITOR/DEVELOPER to determine whether research collaboration is appropriate.
3. If the DEPOSITOR/DEVELOPER determines that the informed research project requires collaboration, a separate agreement will be formulated by both parties to establish rules such as handling of the research results.
4. If the DEPOSITOR/DEVELOPER determines that the informed research project does not requie collaboration, the RECIPIENT agrees to cite the literatire(s) designated by the DEPOSITOR/DEVEVLOPER when publicizing the research results obtained from use of BIOLOGICAL RESOURCE, and to discuss with the DEPOSITOR/DEVELOPER when application for any patents is considered.
5. If the RECIPIENT wants to crossbreed BIOLOGICAL RESOURCE with other genetically engineered mice, the RECIPIENT will obtain a prior written consent from the DEPOSITOR/DEVELOPER.
6. The RECIPIENT will not distribute the BIOLOGICAL RESOURCE to any other individual or entity.
DepositorYoshio Hirabayashi (RIKEN)
Strain Statusan icon for Frozen embryosFrozen embryos
Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
Cryopreserved embryos (within 1 month)
Additional Info.Necessary documents for ordering:
  1. Approval form (Japanese / English)
  2. Order form (Japanese / English)
  3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
  4. CAGGS MTA (English)
  5. Acceptance of responsibility for living modified organism (Japanese / English)

Genotyping protocol -PCR-

BRC mice in Publications

Srimontri P, Endo S, Sakamoto T, Nakayama Y, Kurosaka A, Itohara S, Hirabayashi Y, Kato K.
Sialyltransferase ST3Gal IV deletion protects against temporal lobe epilepsy.
J Neurochem 131(5) 675-87(2014) 25066807

Fujita A, Okuno T, Oda M, Kato K.
Urinary volatilome analysis in a mouse model of anxiety and depression.
PLoS One 15(2) e0229269(2020) 32084196

Kato K.
Differential effects of dietary oils on emotional and cognitive behaviors.
PLoS One 10(3) e0120753(2015) 25799588